The disruptions of the past two years have impacted the life sciences industry in unique ways. Moreover, the new year brings in many more challenges, and supply chain and procurement leaders need to be prepared for what is next.
Life science companies can get ahead of the curve with this definitive guide — GEP Outlook 2023 Life Sciences — that dives deep into the trends for biopharmaceutical and medtech companies in 2023 and provides ways to boost opportunities.
The report looks at six key areas for life sciences companies to focus on and provides recommendations on how to maximize value.
What’s Inside:
- Pricing and technology tools to combat inflation
- Balancing supply surety and austerity measures
- Building infrastructure to take on ESG commitments
This paper is essential reading for supply chain and procurement leaders in the life sciences industry who want to hit the ground running in 2023.
Theme: Strategy and Planning
